REL and chronic kidney disease: Pentoxifylline (PTXF), an FDA-approved drug, can cause selective degradation of c-Rel, without affecting p65.PTXF has been widely used in the therapy of type 2 diabetes mellitus and chronic kidney disease (CKD).